trans-4-Hydroxycrotonic acid (T-HCA), also known as γ-hydroxycrotonic acid (GHC), is an agent used in scientific research to study the GHB receptor. It is an analogue of γ-hydroxybutyric acid (GHB), as well as an active metabolite of GHB. Similarly to GHB, T-HCA has been found to be endogenous to the rat central nervous system, and as a metabolite of GHB, is almost certain to be endogenous to humans as well. T-HCA binds to the high-affinity GHB receptor with 4-fold greater affinity than GHB itself, where it acts as an agonist, but does not bind to the low-affinity GHB binding site, the GABAB receptor. Because of this, T-HCA does not produce sedation. T-HCA has been shown to cause receptor activation-evoked increases in extracellular glutamate concentrations, notably in the hippocampus.

See also

  • HOCPCA
  • γ-Crotonolactone

References


THCA Sixty8.de

HCA launches new CAR TCell therapy LaingBuisson News

THCA Was ist es und was sind die Unterschiede zu THC?

Neue TCA Typen in TYPO3 v12

Thousands of Tennessee patients will have to find new doctors if Cigna